中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
7期
964-965
,共2页
螺杆菌,幽门%细胞色素P450酶系统%埃索美拉唑%变异(遗传学)
螺桿菌,幽門%細胞色素P450酶繫統%埃索美拉唑%變異(遺傳學)
라간균,유문%세포색소P450매계통%애색미랍서%변이(유전학)
Helicobacter pylori%Cytochrome P-450 enzyme system%Esomeprazole%Variation (Genetics)
目的 探讨根除幽门螺杆菌感染失败与细胞色素P450酶2C19(CYP2C19)基因变异的关系.方法 选取60例Hp根除失败患者,对CYP2C19进行基因检测,其中基因强代谢者(EM)49例为观察组,弱代谢者(PM)11例为对照组,均予以使用埃索美拉唑的三联疗法治疗,治疗结束后复查14C转阴率.结果 观察组49例患者Hp根除率为79.6％,对照组为Hp根除率为100.0％,对照组优于观察组(X2=9.475,P＜0.05).结论 Hp根除失败患者中CYP2C19强代谢型(49/60)为多,再次予以埃索美拉唑治疗可提高强代谢型的疗效,但对弱代谢型基因疗效为佳.
目的 探討根除幽門螺桿菌感染失敗與細胞色素P450酶2C19(CYP2C19)基因變異的關繫.方法 選取60例Hp根除失敗患者,對CYP2C19進行基因檢測,其中基因彊代謝者(EM)49例為觀察組,弱代謝者(PM)11例為對照組,均予以使用埃索美拉唑的三聯療法治療,治療結束後複查14C轉陰率.結果 觀察組49例患者Hp根除率為79.6％,對照組為Hp根除率為100.0％,對照組優于觀察組(X2=9.475,P＜0.05).結論 Hp根除失敗患者中CYP2C19彊代謝型(49/60)為多,再次予以埃索美拉唑治療可提高彊代謝型的療效,但對弱代謝型基因療效為佳.
목적 탐토근제유문라간균감염실패여세포색소P450매2C19(CYP2C19)기인변이적관계.방법 선취60례Hp근제실패환자,대CYP2C19진행기인검측,기중기인강대사자(EM)49례위관찰조,약대사자(PM)11례위대조조,균여이사용애색미랍서적삼련요법치료,치료결속후복사14C전음솔.결과 관찰조49례환자Hp근제솔위79.6％,대조조위Hp근제솔위100.0％,대조조우우관찰조(X2=9.475,P＜0.05).결론 Hp근제실패환자중CYP2C19강대사형(49/60)위다,재차여이애색미랍서치료가제고강대사형적료효,단대약대사형기인료효위가.
Objective To investigate the effect of different CYP2C19 genotype on the eradication rate of helicobacter pylori(Hp).Methods 60 cases with Hp eradication failure underwent the CYP2C19 gene detection,in which the gene EM in 49 cases of test group,PM in 11 cases as control group,were given esomeprazole triple therapy,after the end of treatment 14C negative rate was anahyzed.Results 49 cases of test group after treatment,the Hp eradication rate was 79.6％,compared to the control group for the Hp eradication rate was 100.0％,the control group was better than the experimental group with significant difference(X2 =9.475,P ＜ 0.05 ).Conclusion Hp eradication failure in CYP2C19 patients with strong metabolic type (49/60) for much,given again esomeprazole treatment could improve the strong metabotropic efficacy,and espectially for the weak metabolic genotype effect.
